Global GLP-1 Agonists for Obesity Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists have been approved to help treat obesity. GLP-1 agonists have been shown to be effective in promoting weight loss in preclinical and clinical studies.
According to our (Global Info Research) latest study, the global GLP-1 Agonists for Obesity market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global GLP-1 Agonists for Obesity market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global GLP-1 Agonists for Obesity market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030
Global GLP-1 Agonists for Obesity market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030
Global GLP-1 Agonists for Obesity market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030
Global GLP-1 Agonists for Obesity market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for GLP-1 Agonists for Obesity
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global GLP-1 Agonists for Obesity market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
GLP-1 Agonists for Obesity market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe GLP-1 Agonists for Obesity product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of GLP-1 Agonists for Obesity, with price, sales quantity, revenue, and global market share of GLP-1 Agonists for Obesity from 2019 to 2024.
Chapter 3, the GLP-1 Agonists for Obesity competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the GLP-1 Agonists for Obesity breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and GLP-1 Agonists for Obesity market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of GLP-1 Agonists for Obesity.
Chapter 14 and 15, to describe GLP-1 Agonists for Obesity sales channel, distributors, customers, research findings and conclusion.
According to our (Global Info Research) latest study, the global GLP-1 Agonists for Obesity market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global GLP-1 Agonists for Obesity market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global GLP-1 Agonists for Obesity market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030
Global GLP-1 Agonists for Obesity market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030
Global GLP-1 Agonists for Obesity market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030
Global GLP-1 Agonists for Obesity market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for GLP-1 Agonists for Obesity
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global GLP-1 Agonists for Obesity market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
GLP-1 Agonists for Obesity market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Semaglutide
- Tirzepatide
- Liraglutide
- Benaglutide
- Hospital Pharmaty
- Retail Pharmaty
- Others
- Novo Nordisk
- Eli Lilly
- Huadong Medicine
- Shanghai Benemae Pharmaceutical Corporation
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe GLP-1 Agonists for Obesity product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of GLP-1 Agonists for Obesity, with price, sales quantity, revenue, and global market share of GLP-1 Agonists for Obesity from 2019 to 2024.
Chapter 3, the GLP-1 Agonists for Obesity competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the GLP-1 Agonists for Obesity breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and GLP-1 Agonists for Obesity market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of GLP-1 Agonists for Obesity.
Chapter 14 and 15, to describe GLP-1 Agonists for Obesity sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global GLP-1 Agonists for Obesity Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Semaglutide
1.3.3 Tirzepatide
1.3.4 Liraglutide
1.3.5 Benaglutide
1.4 Market Analysis by Application
1.4.1 Overview: Global GLP-1 Agonists for Obesity Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital Pharmaty
1.4.3 Retail Pharmaty
1.4.4 Others
1.5 Global GLP-1 Agonists for Obesity Market Size & Forecast
1.5.1 Global GLP-1 Agonists for Obesity Consumption Value (2019 & 2023 & 2030)
1.5.2 Global GLP-1 Agonists for Obesity Sales Quantity (2019-2030)
1.5.3 Global GLP-1 Agonists for Obesity Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Novo Nordisk
2.1.1 Novo Nordisk Details
2.1.2 Novo Nordisk Major Business
2.1.3 Novo Nordisk GLP-1 Agonists for Obesity Product and Services
2.1.4 Novo Nordisk GLP-1 Agonists for Obesity Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Novo Nordisk Recent Developments/Updates
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business
2.2.3 Eli Lilly GLP-1 Agonists for Obesity Product and Services
2.2.4 Eli Lilly GLP-1 Agonists for Obesity Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Eli Lilly Recent Developments/Updates
2.3 Huadong Medicine
2.3.1 Huadong Medicine Details
2.3.2 Huadong Medicine Major Business
2.3.3 Huadong Medicine GLP-1 Agonists for Obesity Product and Services
2.3.4 Huadong Medicine GLP-1 Agonists for Obesity Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Huadong Medicine Recent Developments/Updates
2.4 Shanghai Benemae Pharmaceutical Corporation
2.4.1 Shanghai Benemae Pharmaceutical Corporation Details
2.4.2 Shanghai Benemae Pharmaceutical Corporation Major Business
2.4.3 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Product and Services
2.4.4 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Shanghai Benemae Pharmaceutical Corporation Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: GLP-1 AGONISTS FOR OBESITY BY MANUFACTURER
3.1 Global GLP-1 Agonists for Obesity Sales Quantity by Manufacturer (2019-2024)
3.2 Global GLP-1 Agonists for Obesity Revenue by Manufacturer (2019-2024)
3.3 Global GLP-1 Agonists for Obesity Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of GLP-1 Agonists for Obesity by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 GLP-1 Agonists for Obesity Manufacturer Market Share in 2023
3.4.3 Top 6 GLP-1 Agonists for Obesity Manufacturer Market Share in 2023
3.5 GLP-1 Agonists for Obesity Market: Overall Company Footprint Analysis
3.5.1 GLP-1 Agonists for Obesity Market: Region Footprint
3.5.2 GLP-1 Agonists for Obesity Market: Company Product Type Footprint
3.5.3 GLP-1 Agonists for Obesity Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global GLP-1 Agonists for Obesity Market Size by Region
4.1.1 Global GLP-1 Agonists for Obesity Sales Quantity by Region (2019-2030)
4.1.2 Global GLP-1 Agonists for Obesity Consumption Value by Region (2019-2030)
4.1.3 Global GLP-1 Agonists for Obesity Average Price by Region (2019-2030)
4.2 North America GLP-1 Agonists for Obesity Consumption Value (2019-2030)
4.3 Europe GLP-1 Agonists for Obesity Consumption Value (2019-2030)
4.4 Asia-Pacific GLP-1 Agonists for Obesity Consumption Value (2019-2030)
4.5 South America GLP-1 Agonists for Obesity Consumption Value (2019-2030)
4.6 Middle East & Africa GLP-1 Agonists for Obesity Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
5.2 Global GLP-1 Agonists for Obesity Consumption Value by Type (2019-2030)
5.3 Global GLP-1 Agonists for Obesity Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
6.2 Global GLP-1 Agonists for Obesity Consumption Value by Application (2019-2030)
6.3 Global GLP-1 Agonists for Obesity Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
7.2 North America GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
7.3 North America GLP-1 Agonists for Obesity Market Size by Country
7.3.1 North America GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2030)
7.3.2 North America GLP-1 Agonists for Obesity Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
8.2 Europe GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
8.3 Europe GLP-1 Agonists for Obesity Market Size by Country
8.3.1 Europe GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2030)
8.3.2 Europe GLP-1 Agonists for Obesity Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific GLP-1 Agonists for Obesity Market Size by Region
9.3.1 Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific GLP-1 Agonists for Obesity Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 South Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
10.2 South America GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
10.3 South America GLP-1 Agonists for Obesity Market Size by Country
10.3.1 South America GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2030)
10.3.2 South America GLP-1 Agonists for Obesity Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa GLP-1 Agonists for Obesity Market Size by Country
11.3.1 Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa GLP-1 Agonists for Obesity Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 GLP-1 Agonists for Obesity Market Drivers
12.2 GLP-1 Agonists for Obesity Market Restraints
12.3 GLP-1 Agonists for Obesity Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of GLP-1 Agonists for Obesity and Key Manufacturers
13.2 Manufacturing Costs Percentage of GLP-1 Agonists for Obesity
13.3 GLP-1 Agonists for Obesity Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 GLP-1 Agonists for Obesity Typical Distributors
14.3 GLP-1 Agonists for Obesity Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global GLP-1 Agonists for Obesity Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Semaglutide
1.3.3 Tirzepatide
1.3.4 Liraglutide
1.3.5 Benaglutide
1.4 Market Analysis by Application
1.4.1 Overview: Global GLP-1 Agonists for Obesity Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital Pharmaty
1.4.3 Retail Pharmaty
1.4.4 Others
1.5 Global GLP-1 Agonists for Obesity Market Size & Forecast
1.5.1 Global GLP-1 Agonists for Obesity Consumption Value (2019 & 2023 & 2030)
1.5.2 Global GLP-1 Agonists for Obesity Sales Quantity (2019-2030)
1.5.3 Global GLP-1 Agonists for Obesity Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Novo Nordisk
2.1.1 Novo Nordisk Details
2.1.2 Novo Nordisk Major Business
2.1.3 Novo Nordisk GLP-1 Agonists for Obesity Product and Services
2.1.4 Novo Nordisk GLP-1 Agonists for Obesity Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Novo Nordisk Recent Developments/Updates
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business
2.2.3 Eli Lilly GLP-1 Agonists for Obesity Product and Services
2.2.4 Eli Lilly GLP-1 Agonists for Obesity Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Eli Lilly Recent Developments/Updates
2.3 Huadong Medicine
2.3.1 Huadong Medicine Details
2.3.2 Huadong Medicine Major Business
2.3.3 Huadong Medicine GLP-1 Agonists for Obesity Product and Services
2.3.4 Huadong Medicine GLP-1 Agonists for Obesity Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Huadong Medicine Recent Developments/Updates
2.4 Shanghai Benemae Pharmaceutical Corporation
2.4.1 Shanghai Benemae Pharmaceutical Corporation Details
2.4.2 Shanghai Benemae Pharmaceutical Corporation Major Business
2.4.3 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Product and Services
2.4.4 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Shanghai Benemae Pharmaceutical Corporation Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: GLP-1 AGONISTS FOR OBESITY BY MANUFACTURER
3.1 Global GLP-1 Agonists for Obesity Sales Quantity by Manufacturer (2019-2024)
3.2 Global GLP-1 Agonists for Obesity Revenue by Manufacturer (2019-2024)
3.3 Global GLP-1 Agonists for Obesity Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of GLP-1 Agonists for Obesity by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 GLP-1 Agonists for Obesity Manufacturer Market Share in 2023
3.4.3 Top 6 GLP-1 Agonists for Obesity Manufacturer Market Share in 2023
3.5 GLP-1 Agonists for Obesity Market: Overall Company Footprint Analysis
3.5.1 GLP-1 Agonists for Obesity Market: Region Footprint
3.5.2 GLP-1 Agonists for Obesity Market: Company Product Type Footprint
3.5.3 GLP-1 Agonists for Obesity Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global GLP-1 Agonists for Obesity Market Size by Region
4.1.1 Global GLP-1 Agonists for Obesity Sales Quantity by Region (2019-2030)
4.1.2 Global GLP-1 Agonists for Obesity Consumption Value by Region (2019-2030)
4.1.3 Global GLP-1 Agonists for Obesity Average Price by Region (2019-2030)
4.2 North America GLP-1 Agonists for Obesity Consumption Value (2019-2030)
4.3 Europe GLP-1 Agonists for Obesity Consumption Value (2019-2030)
4.4 Asia-Pacific GLP-1 Agonists for Obesity Consumption Value (2019-2030)
4.5 South America GLP-1 Agonists for Obesity Consumption Value (2019-2030)
4.6 Middle East & Africa GLP-1 Agonists for Obesity Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
5.2 Global GLP-1 Agonists for Obesity Consumption Value by Type (2019-2030)
5.3 Global GLP-1 Agonists for Obesity Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
6.2 Global GLP-1 Agonists for Obesity Consumption Value by Application (2019-2030)
6.3 Global GLP-1 Agonists for Obesity Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
7.2 North America GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
7.3 North America GLP-1 Agonists for Obesity Market Size by Country
7.3.1 North America GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2030)
7.3.2 North America GLP-1 Agonists for Obesity Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
8.2 Europe GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
8.3 Europe GLP-1 Agonists for Obesity Market Size by Country
8.3.1 Europe GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2030)
8.3.2 Europe GLP-1 Agonists for Obesity Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific GLP-1 Agonists for Obesity Market Size by Region
9.3.1 Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific GLP-1 Agonists for Obesity Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 South Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
10.2 South America GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
10.3 South America GLP-1 Agonists for Obesity Market Size by Country
10.3.1 South America GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2030)
10.3.2 South America GLP-1 Agonists for Obesity Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa GLP-1 Agonists for Obesity Market Size by Country
11.3.1 Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa GLP-1 Agonists for Obesity Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 GLP-1 Agonists for Obesity Market Drivers
12.2 GLP-1 Agonists for Obesity Market Restraints
12.3 GLP-1 Agonists for Obesity Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of GLP-1 Agonists for Obesity and Key Manufacturers
13.2 Manufacturing Costs Percentage of GLP-1 Agonists for Obesity
13.3 GLP-1 Agonists for Obesity Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 GLP-1 Agonists for Obesity Typical Distributors
14.3 GLP-1 Agonists for Obesity Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global GLP-1 Agonists for Obesity Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global GLP-1 Agonists for Obesity Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 4. Novo Nordisk Major Business
Table 5. Novo Nordisk GLP-1 Agonists for Obesity Product and Services
Table 6. Novo Nordisk GLP-1 Agonists for Obesity Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Novo Nordisk Recent Developments/Updates
Table 8. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 9. Eli Lilly Major Business
Table 10. Eli Lilly GLP-1 Agonists for Obesity Product and Services
Table 11. Eli Lilly GLP-1 Agonists for Obesity Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Eli Lilly Recent Developments/Updates
Table 13. Huadong Medicine Basic Information, Manufacturing Base and Competitors
Table 14. Huadong Medicine Major Business
Table 15. Huadong Medicine GLP-1 Agonists for Obesity Product and Services
Table 16. Huadong Medicine GLP-1 Agonists for Obesity Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Huadong Medicine Recent Developments/Updates
Table 18. Shanghai Benemae Pharmaceutical Corporation Basic Information, Manufacturing Base and Competitors
Table 19. Shanghai Benemae Pharmaceutical Corporation Major Business
Table 20. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Product and Services
Table 21. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Shanghai Benemae Pharmaceutical Corporation Recent Developments/Updates
Table 23. Global GLP-1 Agonists for Obesity Sales Quantity by Manufacturer (2019-2024) & (K Dose)
Table 24. Global GLP-1 Agonists for Obesity Revenue by Manufacturer (2019-2024) & (USD Million)
Table 25. Global GLP-1 Agonists for Obesity Average Price by Manufacturer (2019-2024) & (US$/Dose)
Table 26. Market Position of Manufacturers in GLP-1 Agonists for Obesity, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 27. Head Office and GLP-1 Agonists for Obesity Production Site of Key Manufacturer
Table 28. GLP-1 Agonists for Obesity Market: Company Product Type Footprint
Table 29. GLP-1 Agonists for Obesity Market: Company Product Application Footprint
Table 30. GLP-1 Agonists for Obesity New Market Entrants and Barriers to Market Entry
Table 31. GLP-1 Agonists for Obesity Mergers, Acquisition, Agreements, and Collaborations
Table 32. Global GLP-1 Agonists for Obesity Consumption Value by Region (2019-2023-2030) & (USD Million) & CAGR
Table 33. Global GLP-1 Agonists for Obesity Sales Quantity by Region (2019-2024) & (K Dose)
Table 34. Global GLP-1 Agonists for Obesity Sales Quantity by Region (2025-2030) & (K Dose)
Table 35. Global GLP-1 Agonists for Obesity Consumption Value by Region (2019-2024) & (USD Million)
Table 36. Global GLP-1 Agonists for Obesity Consumption Value by Region (2025-2030) & (USD Million)
Table 37. Global GLP-1 Agonists for Obesity Average Price by Region (2019-2024) & (US$/Dose)
Table 38. Global GLP-1 Agonists for Obesity Average Price by Region (2025-2030) & (US$/Dose)
Table 39. Global GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2024) & (K Dose)
Table 40. Global GLP-1 Agonists for Obesity Sales Quantity by Type (2025-2030) & (K Dose)
Table 41. Global GLP-1 Agonists for Obesity Consumption Value by Type (2019-2024) & (USD Million)
Table 42. Global GLP-1 Agonists for Obesity Consumption Value by Type (2025-2030) & (USD Million)
Table 43. Global GLP-1 Agonists for Obesity Average Price by Type (2019-2024) & (US$/Dose)
Table 44. Global GLP-1 Agonists for Obesity Average Price by Type (2025-2030) & (US$/Dose)
Table 45. Global GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2024) & (K Dose)
Table 46. Global GLP-1 Agonists for Obesity Sales Quantity by Application (2025-2030) & (K Dose)
Table 47. Global GLP-1 Agonists for Obesity Consumption Value by Application (2019-2024) & (USD Million)
Table 48. Global GLP-1 Agonists for Obesity Consumption Value by Application (2025-2030) & (USD Million)
Table 49. Global GLP-1 Agonists for Obesity Average Price by Application (2019-2024) & (US$/Dose)
Table 50. Global GLP-1 Agonists for Obesity Average Price by Application (2025-2030) & (US$/Dose)
Table 51. North America GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2024) & (K Dose)
Table 52. North America GLP-1 Agonists for Obesity Sales Quantity by Type (2025-2030) & (K Dose)
Table 53. North America GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2024) & (K Dose)
Table 54. North America GLP-1 Agonists for Obesity Sales Quantity by Application (2025-2030) & (K Dose)
Table 55. North America GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2024) & (K Dose)
Table 56. North America GLP-1 Agonists for Obesity Sales Quantity by Country (2025-2030) & (K Dose)
Table 57. North America GLP-1 Agonists for Obesity Consumption Value by Country (2019-2024) & (USD Million)
Table 58. North America GLP-1 Agonists for Obesity Consumption Value by Country (2025-2030) & (USD Million)
Table 59. Europe GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2024) & (K Dose)
Table 60. Europe GLP-1 Agonists for Obesity Sales Quantity by Type (2025-2030) & (K Dose)
Table 61. Europe GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2024) & (K Dose)
Table 62. Europe GLP-1 Agonists for Obesity Sales Quantity by Application (2025-2030) & (K Dose)
Table 63. Europe GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2024) & (K Dose)
Table 64. Europe GLP-1 Agonists for Obesity Sales Quantity by Country (2025-2030) & (K Dose)
Table 65. Europe GLP-1 Agonists for Obesity Consumption Value by Country (2019-2024) & (USD Million)
Table 66. Europe GLP-1 Agonists for Obesity Consumption Value by Country (2025-2030) & (USD Million)
Table 67. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2024) & (K Dose)
Table 68. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Type (2025-2030) & (K Dose)
Table 69. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2024) & (K Dose)
Table 70. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Application (2025-2030) & (K Dose)
Table 71. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Region (2019-2024) & (K Dose)
Table 72. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Region (2025-2030) & (K Dose)
Table 73. Asia-Pacific GLP-1 Agonists for Obesity Consumption Value by Region (2019-2024) & (USD Million)
Table 74. Asia-Pacific GLP-1 Agonists for Obesity Consumption Value by Region (2025-2030) & (USD Million)
Table 75. South America GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2024) & (K Dose)
Table 76. South America GLP-1 Agonists for Obesity Sales Quantity by Type (2025-2030) & (K Dose)
Table 77. South America GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2024) & (K Dose)
Table 78. South America GLP-1 Agonists for Obesity Sales Quantity by Application (2025-2030) & (K Dose)
Table 79. South America GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2024) & (K Dose)
Table 80. South America GLP-1 Agonists for Obesity Sales Quantity by Country (2025-2030) & (K Dose)
Table 81. South America GLP-1 Agonists for Obesity Consumption Value by Country (2019-2024) & (USD Million)
Table 82. South America GLP-1 Agonists for Obesity Consumption Value by Country (2025-2030) & (USD Million)
Table 83. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2024) & (K Dose)
Table 84. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Type (2025-2030) & (K Dose)
Table 85. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2024) & (K Dose)
Table 86. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Application (2025-2030) & (K Dose)
Table 87. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2024) & (K Dose)
Table 88. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Country (2025-2030) & (K Dose)
Table 89. Middle East & Africa GLP-1 Agonists for Obesity Consumption Value by Country (2019-2024) & (USD Million)
Table 90. Middle East & Africa GLP-1 Agonists for Obesity Consumption Value by Country (2025-2030) & (USD Million)
Table 91. GLP-1 Agonists for Obesity Raw Material
Table 92. Key Manufacturers of GLP-1 Agonists for Obesity Raw Materials
Table 93. GLP-1 Agonists for Obesity Typical Distributors
Table 94. GLP-1 Agonists for Obesity Typical Customers
List of Figures
Figure 1. GLP-1 Agonists for Obesity Picture
Figure 2. Global GLP-1 Agonists for Obesity Revenue by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global GLP-1 Agonists for Obesity Revenue Market Share by Type in 2023
Figure 4. Semaglutide Examples
Figure 5. Tirzepatide Examples
Figure 6. Liraglutide Examples
Figure 7. Benaglutide Examples
Figure 8. Global GLP-1 Agonists for Obesity Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 9. Global GLP-1 Agonists for Obesity Revenue Market Share by Application in 2023
Figure 10. Hospital Pharmaty Examples
Figure 11. Retail Pharmaty Examples
Figure 12. Others Examples
Figure 13. Global GLP-1 Agonists for Obesity Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 14. Global GLP-1 Agonists for Obesity Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 15. Global GLP-1 Agonists for Obesity Sales Quantity (2019-2030) & (K Dose)
Figure 16. Global GLP-1 Agonists for Obesity Price (2019-2030) & (US$/Dose)
Figure 17. Global GLP-1 Agonists for Obesity Sales Quantity Market Share by Manufacturer in 2023
Figure 18. Global GLP-1 Agonists for Obesity Revenue Market Share by Manufacturer in 2023
Figure 19. Producer Shipments of GLP-1 Agonists for Obesity by Manufacturer Sales ($MM) and Market Share (%): 2023
Figure 20. Top 3 GLP-1 Agonists for Obesity Manufacturer (Revenue) Market Share in 2023
Figure 21. Top 6 GLP-1 Agonists for Obesity Manufacturer (Revenue) Market Share in 2023
Figure 22. Global GLP-1 Agonists for Obesity Sales Quantity Market Share by Region (2019-2030)
Figure 23. Global GLP-1 Agonists for Obesity Consumption Value Market Share by Region (2019-2030)
Figure 24. North America GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 25. Europe GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 26. Asia-Pacific GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 27. South America GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 28. Middle East & Africa GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 29. Global GLP-1 Agonists for Obesity Sales Quantity Market Share by Type (2019-2030)
Figure 30. Global GLP-1 Agonists for Obesity Consumption Value Market Share by Type (2019-2030)
Figure 31. Global GLP-1 Agonists for Obesity Average Price by Type (2019-2030) & (US$/Dose)
Figure 32. Global GLP-1 Agonists for Obesity Sales Quantity Market Share by Application (2019-2030)
Figure 33. Global GLP-1 Agonists for Obesity Revenue Market Share by Application (2019-2030)
Figure 34. Global GLP-1 Agonists for Obesity Average Price by Application (2019-2030) & (US$/Dose)
Figure 35. North America GLP-1 Agonists for Obesity Sales Quantity Market Share by Type (2019-2030)
Figure 36. North America GLP-1 Agonists for Obesity Sales Quantity Market Share by Application (2019-2030)
Figure 37. North America GLP-1 Agonists for Obesity Sales Quantity Market Share by Country (2019-2030)
Figure 38. North America GLP-1 Agonists for Obesity Consumption Value Market Share by Country (2019-2030)
Figure 39. United States GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 40. Canada GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 41. Mexico GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 42. Europe GLP-1 Agonists for Obesity Sales Quantity Market Share by Type (2019-2030)
Figure 43. Europe GLP-1 Agonists for Obesity Sales Quantity Market Share by Application (2019-2030)
Figure 44. Europe GLP-1 Agonists for Obesity Sales Quantity Market Share by Country (2019-2030)
Figure 45. Europe GLP-1 Agonists for Obesity Consumption Value Market Share by Country (2019-2030)
Figure 46. Germany GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 47. France GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 48. United Kingdom GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 49. Russia GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 50. Italy GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 51. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity Market Share by Type (2019-2030)
Figure 52. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity Market Share by Application (2019-2030)
Figure 53. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity Market Share by Region (2019-2030)
Figure 54. Asia-Pacific GLP-1 Agonists for Obesity Consumption Value Market Share by Region (2019-2030)
Figure 55. China GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 56. Japan GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 57. South Korea GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 58. India GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 59. Southeast Asia GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 60. Australia GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 61. South America GLP-1 Agonists for Obesity Sales Quantity Market Share by Type (2019-2030)
Figure 62. South America GLP-1 Agonists for Obesity Sales Quantity Market Share by Application (2019-2030)
Figure 63. South America GLP-1 Agonists for Obesity Sales Quantity Market Share by Country (2019-2030)
Figure 64. South America GLP-1 Agonists for Obesity Consumption Value Market Share by Country (2019-2030)
Figure 65. Brazil GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 66. Argentina GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 67. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity Market Share by Type (2019-2030)
Figure 68. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity Market Share by Application (2019-2030)
Figure 69. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity Market Share by Country (2019-2030)
Figure 70. Middle East & Africa GLP-1 Agonists for Obesity Consumption Value Market Share by Country (2019-2030)
Figure 71. Turkey GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 72. Egypt GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 73. Saudi Arabia GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 74. South Africa GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 75. GLP-1 Agonists for Obesity Market Drivers
Figure 76. GLP-1 Agonists for Obesity Market Restraints
Figure 77. GLP-1 Agonists for Obesity Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of GLP-1 Agonists for Obesity in 2023
Figure 80. Manufacturing Process Analysis of GLP-1 Agonists for Obesity
Figure 81. GLP-1 Agonists for Obesity Industrial Chain
Figure 82. Sales Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
Table 1. Global GLP-1 Agonists for Obesity Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global GLP-1 Agonists for Obesity Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 4. Novo Nordisk Major Business
Table 5. Novo Nordisk GLP-1 Agonists for Obesity Product and Services
Table 6. Novo Nordisk GLP-1 Agonists for Obesity Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Novo Nordisk Recent Developments/Updates
Table 8. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 9. Eli Lilly Major Business
Table 10. Eli Lilly GLP-1 Agonists for Obesity Product and Services
Table 11. Eli Lilly GLP-1 Agonists for Obesity Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Eli Lilly Recent Developments/Updates
Table 13. Huadong Medicine Basic Information, Manufacturing Base and Competitors
Table 14. Huadong Medicine Major Business
Table 15. Huadong Medicine GLP-1 Agonists for Obesity Product and Services
Table 16. Huadong Medicine GLP-1 Agonists for Obesity Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Huadong Medicine Recent Developments/Updates
Table 18. Shanghai Benemae Pharmaceutical Corporation Basic Information, Manufacturing Base and Competitors
Table 19. Shanghai Benemae Pharmaceutical Corporation Major Business
Table 20. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Product and Services
Table 21. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Shanghai Benemae Pharmaceutical Corporation Recent Developments/Updates
Table 23. Global GLP-1 Agonists for Obesity Sales Quantity by Manufacturer (2019-2024) & (K Dose)
Table 24. Global GLP-1 Agonists for Obesity Revenue by Manufacturer (2019-2024) & (USD Million)
Table 25. Global GLP-1 Agonists for Obesity Average Price by Manufacturer (2019-2024) & (US$/Dose)
Table 26. Market Position of Manufacturers in GLP-1 Agonists for Obesity, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 27. Head Office and GLP-1 Agonists for Obesity Production Site of Key Manufacturer
Table 28. GLP-1 Agonists for Obesity Market: Company Product Type Footprint
Table 29. GLP-1 Agonists for Obesity Market: Company Product Application Footprint
Table 30. GLP-1 Agonists for Obesity New Market Entrants and Barriers to Market Entry
Table 31. GLP-1 Agonists for Obesity Mergers, Acquisition, Agreements, and Collaborations
Table 32. Global GLP-1 Agonists for Obesity Consumption Value by Region (2019-2023-2030) & (USD Million) & CAGR
Table 33. Global GLP-1 Agonists for Obesity Sales Quantity by Region (2019-2024) & (K Dose)
Table 34. Global GLP-1 Agonists for Obesity Sales Quantity by Region (2025-2030) & (K Dose)
Table 35. Global GLP-1 Agonists for Obesity Consumption Value by Region (2019-2024) & (USD Million)
Table 36. Global GLP-1 Agonists for Obesity Consumption Value by Region (2025-2030) & (USD Million)
Table 37. Global GLP-1 Agonists for Obesity Average Price by Region (2019-2024) & (US$/Dose)
Table 38. Global GLP-1 Agonists for Obesity Average Price by Region (2025-2030) & (US$/Dose)
Table 39. Global GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2024) & (K Dose)
Table 40. Global GLP-1 Agonists for Obesity Sales Quantity by Type (2025-2030) & (K Dose)
Table 41. Global GLP-1 Agonists for Obesity Consumption Value by Type (2019-2024) & (USD Million)
Table 42. Global GLP-1 Agonists for Obesity Consumption Value by Type (2025-2030) & (USD Million)
Table 43. Global GLP-1 Agonists for Obesity Average Price by Type (2019-2024) & (US$/Dose)
Table 44. Global GLP-1 Agonists for Obesity Average Price by Type (2025-2030) & (US$/Dose)
Table 45. Global GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2024) & (K Dose)
Table 46. Global GLP-1 Agonists for Obesity Sales Quantity by Application (2025-2030) & (K Dose)
Table 47. Global GLP-1 Agonists for Obesity Consumption Value by Application (2019-2024) & (USD Million)
Table 48. Global GLP-1 Agonists for Obesity Consumption Value by Application (2025-2030) & (USD Million)
Table 49. Global GLP-1 Agonists for Obesity Average Price by Application (2019-2024) & (US$/Dose)
Table 50. Global GLP-1 Agonists for Obesity Average Price by Application (2025-2030) & (US$/Dose)
Table 51. North America GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2024) & (K Dose)
Table 52. North America GLP-1 Agonists for Obesity Sales Quantity by Type (2025-2030) & (K Dose)
Table 53. North America GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2024) & (K Dose)
Table 54. North America GLP-1 Agonists for Obesity Sales Quantity by Application (2025-2030) & (K Dose)
Table 55. North America GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2024) & (K Dose)
Table 56. North America GLP-1 Agonists for Obesity Sales Quantity by Country (2025-2030) & (K Dose)
Table 57. North America GLP-1 Agonists for Obesity Consumption Value by Country (2019-2024) & (USD Million)
Table 58. North America GLP-1 Agonists for Obesity Consumption Value by Country (2025-2030) & (USD Million)
Table 59. Europe GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2024) & (K Dose)
Table 60. Europe GLP-1 Agonists for Obesity Sales Quantity by Type (2025-2030) & (K Dose)
Table 61. Europe GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2024) & (K Dose)
Table 62. Europe GLP-1 Agonists for Obesity Sales Quantity by Application (2025-2030) & (K Dose)
Table 63. Europe GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2024) & (K Dose)
Table 64. Europe GLP-1 Agonists for Obesity Sales Quantity by Country (2025-2030) & (K Dose)
Table 65. Europe GLP-1 Agonists for Obesity Consumption Value by Country (2019-2024) & (USD Million)
Table 66. Europe GLP-1 Agonists for Obesity Consumption Value by Country (2025-2030) & (USD Million)
Table 67. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2024) & (K Dose)
Table 68. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Type (2025-2030) & (K Dose)
Table 69. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2024) & (K Dose)
Table 70. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Application (2025-2030) & (K Dose)
Table 71. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Region (2019-2024) & (K Dose)
Table 72. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity by Region (2025-2030) & (K Dose)
Table 73. Asia-Pacific GLP-1 Agonists for Obesity Consumption Value by Region (2019-2024) & (USD Million)
Table 74. Asia-Pacific GLP-1 Agonists for Obesity Consumption Value by Region (2025-2030) & (USD Million)
Table 75. South America GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2024) & (K Dose)
Table 76. South America GLP-1 Agonists for Obesity Sales Quantity by Type (2025-2030) & (K Dose)
Table 77. South America GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2024) & (K Dose)
Table 78. South America GLP-1 Agonists for Obesity Sales Quantity by Application (2025-2030) & (K Dose)
Table 79. South America GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2024) & (K Dose)
Table 80. South America GLP-1 Agonists for Obesity Sales Quantity by Country (2025-2030) & (K Dose)
Table 81. South America GLP-1 Agonists for Obesity Consumption Value by Country (2019-2024) & (USD Million)
Table 82. South America GLP-1 Agonists for Obesity Consumption Value by Country (2025-2030) & (USD Million)
Table 83. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Type (2019-2024) & (K Dose)
Table 84. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Type (2025-2030) & (K Dose)
Table 85. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Application (2019-2024) & (K Dose)
Table 86. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Application (2025-2030) & (K Dose)
Table 87. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Country (2019-2024) & (K Dose)
Table 88. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity by Country (2025-2030) & (K Dose)
Table 89. Middle East & Africa GLP-1 Agonists for Obesity Consumption Value by Country (2019-2024) & (USD Million)
Table 90. Middle East & Africa GLP-1 Agonists for Obesity Consumption Value by Country (2025-2030) & (USD Million)
Table 91. GLP-1 Agonists for Obesity Raw Material
Table 92. Key Manufacturers of GLP-1 Agonists for Obesity Raw Materials
Table 93. GLP-1 Agonists for Obesity Typical Distributors
Table 94. GLP-1 Agonists for Obesity Typical Customers
List of Figures
Figure 1. GLP-1 Agonists for Obesity Picture
Figure 2. Global GLP-1 Agonists for Obesity Revenue by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global GLP-1 Agonists for Obesity Revenue Market Share by Type in 2023
Figure 4. Semaglutide Examples
Figure 5. Tirzepatide Examples
Figure 6. Liraglutide Examples
Figure 7. Benaglutide Examples
Figure 8. Global GLP-1 Agonists for Obesity Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 9. Global GLP-1 Agonists for Obesity Revenue Market Share by Application in 2023
Figure 10. Hospital Pharmaty Examples
Figure 11. Retail Pharmaty Examples
Figure 12. Others Examples
Figure 13. Global GLP-1 Agonists for Obesity Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 14. Global GLP-1 Agonists for Obesity Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 15. Global GLP-1 Agonists for Obesity Sales Quantity (2019-2030) & (K Dose)
Figure 16. Global GLP-1 Agonists for Obesity Price (2019-2030) & (US$/Dose)
Figure 17. Global GLP-1 Agonists for Obesity Sales Quantity Market Share by Manufacturer in 2023
Figure 18. Global GLP-1 Agonists for Obesity Revenue Market Share by Manufacturer in 2023
Figure 19. Producer Shipments of GLP-1 Agonists for Obesity by Manufacturer Sales ($MM) and Market Share (%): 2023
Figure 20. Top 3 GLP-1 Agonists for Obesity Manufacturer (Revenue) Market Share in 2023
Figure 21. Top 6 GLP-1 Agonists for Obesity Manufacturer (Revenue) Market Share in 2023
Figure 22. Global GLP-1 Agonists for Obesity Sales Quantity Market Share by Region (2019-2030)
Figure 23. Global GLP-1 Agonists for Obesity Consumption Value Market Share by Region (2019-2030)
Figure 24. North America GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 25. Europe GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 26. Asia-Pacific GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 27. South America GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 28. Middle East & Africa GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 29. Global GLP-1 Agonists for Obesity Sales Quantity Market Share by Type (2019-2030)
Figure 30. Global GLP-1 Agonists for Obesity Consumption Value Market Share by Type (2019-2030)
Figure 31. Global GLP-1 Agonists for Obesity Average Price by Type (2019-2030) & (US$/Dose)
Figure 32. Global GLP-1 Agonists for Obesity Sales Quantity Market Share by Application (2019-2030)
Figure 33. Global GLP-1 Agonists for Obesity Revenue Market Share by Application (2019-2030)
Figure 34. Global GLP-1 Agonists for Obesity Average Price by Application (2019-2030) & (US$/Dose)
Figure 35. North America GLP-1 Agonists for Obesity Sales Quantity Market Share by Type (2019-2030)
Figure 36. North America GLP-1 Agonists for Obesity Sales Quantity Market Share by Application (2019-2030)
Figure 37. North America GLP-1 Agonists for Obesity Sales Quantity Market Share by Country (2019-2030)
Figure 38. North America GLP-1 Agonists for Obesity Consumption Value Market Share by Country (2019-2030)
Figure 39. United States GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 40. Canada GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 41. Mexico GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 42. Europe GLP-1 Agonists for Obesity Sales Quantity Market Share by Type (2019-2030)
Figure 43. Europe GLP-1 Agonists for Obesity Sales Quantity Market Share by Application (2019-2030)
Figure 44. Europe GLP-1 Agonists for Obesity Sales Quantity Market Share by Country (2019-2030)
Figure 45. Europe GLP-1 Agonists for Obesity Consumption Value Market Share by Country (2019-2030)
Figure 46. Germany GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 47. France GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 48. United Kingdom GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 49. Russia GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 50. Italy GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 51. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity Market Share by Type (2019-2030)
Figure 52. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity Market Share by Application (2019-2030)
Figure 53. Asia-Pacific GLP-1 Agonists for Obesity Sales Quantity Market Share by Region (2019-2030)
Figure 54. Asia-Pacific GLP-1 Agonists for Obesity Consumption Value Market Share by Region (2019-2030)
Figure 55. China GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 56. Japan GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 57. South Korea GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 58. India GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 59. Southeast Asia GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 60. Australia GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 61. South America GLP-1 Agonists for Obesity Sales Quantity Market Share by Type (2019-2030)
Figure 62. South America GLP-1 Agonists for Obesity Sales Quantity Market Share by Application (2019-2030)
Figure 63. South America GLP-1 Agonists for Obesity Sales Quantity Market Share by Country (2019-2030)
Figure 64. South America GLP-1 Agonists for Obesity Consumption Value Market Share by Country (2019-2030)
Figure 65. Brazil GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 66. Argentina GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 67. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity Market Share by Type (2019-2030)
Figure 68. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity Market Share by Application (2019-2030)
Figure 69. Middle East & Africa GLP-1 Agonists for Obesity Sales Quantity Market Share by Country (2019-2030)
Figure 70. Middle East & Africa GLP-1 Agonists for Obesity Consumption Value Market Share by Country (2019-2030)
Figure 71. Turkey GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 72. Egypt GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 73. Saudi Arabia GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 74. South Africa GLP-1 Agonists for Obesity Consumption Value (2019-2030) & (USD Million)
Figure 75. GLP-1 Agonists for Obesity Market Drivers
Figure 76. GLP-1 Agonists for Obesity Market Restraints
Figure 77. GLP-1 Agonists for Obesity Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of GLP-1 Agonists for Obesity in 2023
Figure 80. Manufacturing Process Analysis of GLP-1 Agonists for Obesity
Figure 81. GLP-1 Agonists for Obesity Industrial Chain
Figure 82. Sales Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
